NDAORALTABLET
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CARTROL (carteolol hydrochloride) by AbbVie is clinical pharmacology carteolol is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. Approved for hypertension, glaucoma. First approved in 1988.
Drug data last refreshed 23h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARTROL (carteolol hydrochloride) is a nonselective beta-adrenergic blocking agent with intrinsic sympathomimetic activity approved for hypertension and glaucoma. It reduces intraocular pressure by approximately 22–25% and lowers blood pressure through cardiac output reduction and peripheral vascular effects. The drug is administered orally as a tablet and has been marketed since 1988.
LOE Approaching
Product is approaching loss of exclusivity with declining market relevance; supporting teams typically shrink in size and shift focus to transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Carteolol is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. Carteolol Hydrochloride reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by…
Indications (2)
Worked on CARTROL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.